Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

40.500
+0.5001.25%
Volume:7.06M
Turnover:284.44M
Market Cap:167.59B
PE:45.47
High:40.600
Open:40.000
Low:39.720
Close:40.000
52wk High:44.000
52wk Low:16.200
Shares:4.14B
HK Float Shares:4.14B
Volume Ratio:0.36
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.891
ROE:10.50%
ROA:5.89%
PB:3.28
PE(LYR):45.47
PS:7.36

Loading ...

Wuxi Biologics (Cayman) Stock Advances 1.3% in Hong Kong

Dow Jones
·
Feb 16

BUZZ-CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares

Reuters
·
Feb 16

CANBRIDGE-B Shares Surge Following Discounted Share Placement

Stock News
·
Feb 16

JPMorgan Raises WUXI BIO Target Price to HK$51 Following Strong Earnings Beat and Robust Order Pipeline

Stock News
·
Feb 13

Wuxi Biologics (Cayman) Stock Sheds 3.2% in Hong Kong

Dow Jones
·
Feb 13

Vertex posts FY2025 GAAP operating income of USD 4.17 billion

Reuters
·
Feb 13

Morgan Stanley Forecasts WuXi Biologics Shares to Rise in Next 45 Days, Raises Target Price to HK$50

Stock News
·
Feb 12

WUXI BIO Shares Surge Over 6% Again on Stronger-Than-Expected Second-Half Profit and Margin Expansion

Stock News
·
Feb 12

Wuxi Biologics (Cayman) Stock Rallies 3.4% in Hong Kong

Dow Jones
·
Feb 11

China stocks steady as metals rally counters consumer, AI losses

Reuters
·
Feb 11

BUZZ-WuXi Biologics climbs to 4-month high on robust earnings estimates

Reuters
·
Feb 11

BRIEF-Wuxi Biologics FY Revenue RMB21,790 Million

Reuters
·
Feb 11

WUXI BIO Issues Positive Profit Alert, Anticipates 46.3% Rise in Annual Shareholder Profit

Stock News
·
Feb 11

WuXi Biologics (Cayman) Inc. (Stock Code: 2269) Anticipates Notable Profits Growth for FY2025

Bulletin Express
·
Feb 11

WuXi Biologics (Cayman) Inc. (2269) Schedules Board Meeting to Review 2025 Annual Results

Bulletin Express
·
Feb 11

WuXi Biologics Board to Approve Annual Results

Reuters
·
Feb 11

Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion

Reuters
·
Feb 11

WuXi Biologics -FY Profit Expected to Increase to RMB5,733 Mln

THOMSON REUTERS
·
Feb 11

Biopharmaceutical Stocks Show Broad Gains with CSPC PHARMA Leading with Over 7% Rise

Deep News
·
Feb 10

CRO Stocks Lead Gains as Biopharma Investment and Cross-Border Deals Rebound

Stock News
·
Feb 10